NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 13:42இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 PAT Rises 44.8% YoY to ₹143.5 Cr; Quarterly Revenue Crosses ₹900 Cr Milestone
Marksans Pharma reported a 30.5% YoY rise in operating revenue to ₹940.2 crore for Q2 FY27, crossing ₹900 crore in quarterly revenue for the first time. Operating EBITDA rose 48.3% YoY to ₹214.3 crore with margins expanding 274 bps to 22.8%, while PAT increased 44.8% YoY to ₹143.5 crore. For H1 FY27, PAT nearly doubled to ₹302.9 crore (up 92.5% YoY), reaching over 70% of the entire FY26 net profit (₹420 crore). The balance sheet remains robust with net cash expanding to ₹1,095 crore and H1 operating cash flow surging 4.3x to ₹322 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma published its Q2 and H1 FY27 earnings press release, demonstrating quarterly revenue above ₹900 crore and EBITDA of ₹214.3 crore.
ஏன் இது முக்கியம்Topline and margin expansion reflect successful integration of acquired assets, organic volume growth in the UK and US, and significant operating cash flow generation.
📅 குறுகிய காலம்Strong operational beat YoY is likely to support positive market sentiment, though sequential PAT softened 10.0% QoQ from ₹159.4 crore in Q1 FY27.
📈 நீண்ட காலம்With net cash of ₹1,095 crore and expanding European and US footprint, the company is structurally positioned to execute strategic M&A and sustain organic formulations growth.
Pricing erosion risks in Rx portfolios and US consumer environment softness
👀 கவனிக்க வேண்டியவை
Track management commentary in the earnings conference call scheduled for November 5, 2026, focusing on gross margin sustainability and the integration of European front-end QliniQ.
Marksans Pharma Reports Q2 FY27 Results; Acquires European Entities QliniQ & ABCnow for €8.6M
Marksans Pharma declared its Q2 and H1 FY27 results (period ended September 30, 2026), with standalone H1 FY27 revenue from operations at ₹7,042.41 million compared to ₹6,309.91 million in H1 FY26. Standalone net profit for Q2 FY27 stood at ₹855.42 million versus ₹690.92 million in Q2 FY26. Alongside results, the company completed two strategic European acquisitions: 100% of Netherlands-based QliniQ B.V. for EUR 7.50 million and Germany-based ABCnow GmbH for EUR 1.10 million to build direct frontend distribution.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma released its Q2/H1 FY27 financial results and officially reported two European frontend acquisitions (QliniQ B.V. and ABCnow GmbH) totaling EUR 8.60 million.
ஏன் இது முக்கியம்The acquisitions provide direct sales and distribution capabilities in the Netherlands and Germany, advancing the company's European footprint beyond the UK.
📅 குறுகிய காலம்Solid operational performance and European market expansion provide steady momentum over the coming weeks.
📈 நீண்ட காலம்Direct distribution access in Germany and the Netherlands structurally enhances operating leverage and reduces dependence on intermediaries and the UK market.
⚠ அபாய எச்சரிக்கைகள்
Provisional purchase price allocations under Ind AS 103 pending final fair value determination
Integration risks in foreign markets (Germany, Netherlands)
👀 கவனிக்க வேண்டியவை
Track the integration and margin profile of newly acquired European subsidiaries (QliniQ and ABCnow) and monitor ramp-up of the Teva manufacturing facility.
Marksans Pharma Q1 FY27 Concall: PAT Jumps 174% YoY to ₹159 Cr; Targets ₹4,000 Cr Revenue in 2 Yrs
Marksans Pharma reported robust Q1 FY27 operational results with revenue growing 35.6% YoY to ₹840.8 crore, driven by a 74.7% surge in the UK and Europe segment to ₹356 crore (aided by the QliniQ acquisition). EBITDA increased 112.8% YoY to ₹213 crore with margins expanding 919 bps to 25.3%, while PAT climbed 173.9% YoY to ₹159.4 crore. The company generated free cash flow of ₹152 crore, taking its cash balance above ₹1,000 crore to ₹1,058 crore. Management reiterated its growth guidance of 15-20% for FY27 and maintained its strategic target to reach ₹4,000 crore in revenue within two years.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript of the Q1 FY27 investor/analyst earnings call held on August 13, 2026.
ஏன் இது முக்கியம்Provides management commentary on European expansion, margin drivers (operating leverage and low-cost inventory benefit), and strategic capital allocation for inorganic opportunities using its ₹1,000+ crore cash balance.
📅 குறுகிய காலம்Positive sentiment from record quarterly performance, strong cash conversion, and lower working capital cycle.
📈 நீண்ட காலம்Underpins the company's trajectory toward achieving ₹4,000 crore revenue within two years through European front-end acquisitions and US private label OTC expansion.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical risks and elevated freight/solvent raw material costs that could compress gross margins towards the 55-56% baseline.
Potential integration risks with newly acquired European entities (QliniQ and ABCnow).
👀 கவனிக்க வேண்டியவை
Track the integration and performance of European acquisitions (QliniQ and ABCnow GmbH) along with sustainability of gross margins (management normalized target of 55-56% vs 59.1% in Q1).
174% PAT Growth: Marksans Pharma Reports Record Q1FY27 with ₹213 Cr EBITDA
Marksans Pharma delivered a record-breaking Q1FY27, with PAT surging 173.9% YoY to ₹159.4 cr and EBITDA rising 112.8% to ₹213 cr. Revenue grew 35.6% YoY to ₹840.8 cr, driven by a 74.7% jump in the UK & Europe segment, which hit an all-time high of ₹356 cr. EBITDA margins expanded significantly by 919 bps YoY to 25.3%, reflecting strong operating leverage and the integration of European acquisitions. The company's cash balance crossed the ₹1,000 cr milestone for the first time, reaching ₹1,058 cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans has achieved a new baseline of profitability with record margins and revenue, significantly exceeding its TTM OPM of 21.5%.
ஏன் இது முக்கியம்The results validate the company's strategy of expanding its front-end presence in Europe (via QliniQ) and scaling its manufacturing capacity, leading to superior operating leverage and cash generation.
📅 குறுகிய காலம்The stock is likely to react positively to the substantial earnings beat and the milestone of crossing ₹1,000 cr in cash.
📈 நீண்ட காலம்The structural shift toward higher-margin European markets and a debt-free, cash-rich balance sheet supports the company's long-term goal of reaching ₹3,000 cr in revenue.
⚠ அபாய எச்சரிக்கைகள்
Pricing pressure in the UK market
Geopolitical delays impacting RoW shipments
Integration risks of newly acquired European entities
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 25%+ EBITDA margins in upcoming quarters and watch for the deployment of the ₹1,058 cr cash reserve toward the company's stated inorganic growth strategy.
174% PAT growth: Marksans Pharma Q1 profit hits ₹159.4 Cr; expands in Europe via acquisitions
Marksans Pharma reported a strong Q1 FY27 with consolidated Profit After Tax (PAT) surging 173.9% YoY to ₹159.41 Cr. The company significantly expanded its European footprint by acquiring 100% of QliniQ B.V. (Netherlands) for EUR 7.50 Million and entering a definitive agreement for ABCnow GmbH (Germany) for EUR 1.10 Million. Consolidated EPS improved to ₹3.47 from ₹1.28 in the previous year's quarter. While standalone revenue growth was flat at 0.4% YoY, the consolidated performance reflects strong contributions from subsidiaries and new acquisitions.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma reported a massive jump in consolidated profitability and completed two strategic acquisitions to establish a direct frontend presence in the Netherlands and Germany.
ஏன் இது முக்கியம்The acquisitions shift the business model from distributor-led to direct frontend sales in key European markets, which is critical for the company's goal to reach ₹3,000 Cr in revenue and become a top 5 private label OTC player.
Consolidated PAT (Q1): ₹159.41 கோடிYoY PAT Growth: 173.9%Total Acquisition Value: EUR 8.60 MillionConsolidated EPS: ₹3.47Standalone Revenue: ₹321.19 கோடிAcquisition vs TTM Revenue: ~3.1%
📅 குறுகிய காலம்The stock is likely to see positive momentum driven by the triple-digit profit growth and the strategic expansion into the European market.
📈 நீண்ட காலம்Structural growth is supported by the transition to a frontend-led model in Europe and the doubling of low-cost manufacturing capacity in India.
⚠ அபாய எச்சரிக்கைகள்
Integration risks of European acquisitions
Pricing pressure in the UK market
Elevated freight costs due to Red Sea crisis
👀 கவனிக்க வேண்டியவை
Monitor the integration of the new European subsidiaries and their impact on consolidated margins. Watch for the ramp-up of the Teva facility (Unit 2) and progress on the planned doubling of India-based manufacturing capacity to 16 billion units.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Marksans Pharma Completes 100% Acquisition of Germany-based ABCnow GmbH
Marksans Pharma has successfully completed the acquisition of 100% share capital of ABCnow GmbH, based in Germany. This move aligns with the company's stated strategic goal to reach Rs 3,000 Cr in revenue by expanding its footprint in the European market. While the acquisition cost was not disclosed in this filing, the company had previously raised Rs 372.40 Cr via warrants to fund such growth initiatives. This acquisition follows an initial intimation made on July 8, 2026, and marks a concrete step in the company's geographic diversification strategy.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுMarksans Pharma has finalized the takeover of ABCnow GmbH, transitioning it from a target to a 100% owned subsidiary.
ஏன் இது முக்கியம்The acquisition provides a direct entry point into the German pharmaceutical market, reducing dependence on the US and UK markets where the company has faced pricing pressures and margin compression (258 bps decline in Q2 FY26).
📅 குறுகிய காலம்The completion of the acquisition is likely to be viewed positively by the market as it demonstrates execution of the company's stated expansion strategy.
📈 நீண்ட காலம்This is a structural move to establish a presence in Germany, which, if scaled successfully alongside the planned doubling of Indian capacity, could significantly contribute to the Rs 3,000 Cr revenue goal.
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming quarterly results for the financial contribution of the German entity and management's guidance on the integration timeline. Watch for updates on regulatory filings in Germany which are critical for organic growth in that region.
Marksans Pharma to Acquire 100% of German Firm ABCnow GmbH for € 892,384
Marksans Pharma has entered into a definitive agreement to acquire 100% of ABCnow GmbH, a German pharmaceutical distributor, for a cash consideration of € 892,384 (approx. ₹8.1 Cr). The acquisition provides Marksans with a direct front-end sales and marketing infrastructure in Germany, facilitating the distribution of products manufactured in its India, UK, and USA facilities. While the target's 2025 revenue of € 227,233 is small (less than 0.5% of Marksans' TTM revenue of ₹2,650 Cr), it fulfills a stated strategic goal to expand into the German market. The transaction is expected to close by July 31, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுMarksans has transitioned from an organic entry plan in Germany to an inorganic acquisition of a local distribution front-end.
ஏன் இது முக்கியம்This provides the company with direct market access in Germany, a key regulated market, supporting its long-term goal of reaching ₹3,000 Cr in revenue and reducing reliance on third-party distributors.
Cost of acquisition: € 892,384Target Revenue (2025): € 227,233.69Acquisition vs TTM Revenue: ~0.31%Expected Completion Date: 31 ஜூலை 2026
📅 குறுகிய காலம்The small financial scale of the deal suggests limited immediate impact on the stock price, though it confirms management's execution of its stated expansion strategy.
📈 நீண்ட காலம்Structurally significant as it establishes a base in Germany; the long-term value depends on Marksans' ability to scale its OTC and prescription products through this new European hub.
⚠ அபாய எச்சரிக்கைகள்
Target revenue showed a significant decline from 2024 to 2025
Integration risk of a foreign distribution entity
👀 கவனிக்க வேண்டியவை
Watch for the successful integration of the German front-end and the timeline for launching Marksans' existing product portfolio through this new distribution channel.
₹ 0.90 Dividend: Marksans Pharma Sets August 20 as Record Date for FY26 Final Dividend
Marksans Pharma has finalized the timeline for its FY26 final dividend of ₹ 0.90 per share (90% of face value). The record date to determine shareholder eligibility is fixed for August 20, 2026, with the Annual General Meeting (AGM) scheduled for August 27, 2026. If approved at the AGM, the dividend will be paid starting September 10, 2026. This follows the board's recommendation made on May 26, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has moved from a dividend recommendation to fixing the specific execution dates (Record Date and AGM) for the FY26 payout.
ஏன் இது முக்கியம்While the dividend yield is modest at approximately 0.33%, it confirms the company's commitment to regular shareholder distributions alongside its growth investments in capacity expansion.
Dividend per share: ₹ 0.90ரெக்கார்ட் தேதி: ஆகஸ்ட் 20, 2026டிவிடெண்ட் ஈல்ட்: ~0.33%TTM EPS: ₹ 9.00AGM Date: ஆகஸ்ட் 27, 2026
📅 குறுகிய காலம்The stock may see minor price adjustments around the ex-dividend date in August, though the small yield suggests minimal volatility from this event.
📈 நீண்ட காலம்Limited; this is a routine administrative filing for an annual dividend distribution.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend must hold the shares before the ex-dividend date (typically one day prior to the August 20 record date). Monitor the upcoming AGM for management commentary on the ₹ 3,000 Cr revenue target.
Marksans Pharma FY26 Net Profit Jumps 60% to ₹3,007 Million; Re-submits Legible Results
Marksans Pharma re-submitted its audited financial results for FY26 in a machine-readable format following a request from the NSE. For the full year ended March 31, 2026, the company reported a significant 60% growth in Profit After Tax (PAT) to ₹3,006.98 million compared to ₹1,882.72 million in the previous year. Revenue from operations grew by 14.2% to ₹13,414.76 million. The company's EPS improved from ₹4.15 to ₹6.64, reflecting strong operational performance and margin expansion.
முக்கிய அம்சங்கள்
Full-year FY26 Revenue from operations increased 14.2% YoY to ₹13,414.76 million.Net Profit (PAT) for FY26 surged 59.7% to ₹3,006.98 million from ₹1,882.72 million in FY25.Earnings Per Share (EPS) rose significantly to ₹6.64 for the full year, up from ₹4.15 in the previous fiscal.Profit Before Tax (PBT) for the year stood at ₹3,915.43 million, a 61% increase over FY25.Total Comprehensive Income for FY26 reached ₹3,017.39 million, compared to ₹1,879.71 million in FY25.
👀 கவனிக்க வேண்டியவை
The strong growth in both top-line and bottom-line figures indicates robust business momentum and improved profitability. Investors should focus on the fundamental growth trajectory rather than the minor administrative re-filing requested by the exchange.
Marksans Pharma Completes 100% Acquisition of Netherlands-based QliniQ B.V.
Marksans Pharma Limited has successfully finalized the acquisition of 100% share capital of QliniQ B.V., a company based in the Netherlands. This announcement follows the initial intimation provided on June 1, 2026, confirming the completion of the transaction. The acquisition is a strategic step to enhance the company's presence in the European pharmaceutical market. Investors should view this as a completion of a growth-oriented expansion move.
முக்கிய அம்சங்கள்
Successfully completed the acquisition of 100% share capital of QliniQ B.V.The target company, QliniQ B.V., is based in the Netherlands, expanding Marksans' European footprint.The transaction was concluded on June 16, 2026, following the initial agreement on June 1, 2026.The acquisition aligns with the company's strategy for international inorganic growth.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration process and look for the financial contribution of QliniQ B.V. in the upcoming quarterly earnings reports. The stock remains a 'Watch' for long-term growth driven by international expansion.
Marksans Pharma Credit Outlook Upgraded to Positive; Ratings Affirmed at IND AA-
India Ratings and Research (Fitch Group) has revised the outlook for Marksans Pharma's bank loan facilities from 'Stable' to 'Positive'. The agency affirmed the long-term rating at 'IND AA-' and the short-term rating at 'IND A1+' for facilities totaling ₹195.75 crore. This outlook revision indicates a potential for a future rating upgrade, reflecting the company's strengthening credit profile and financial stability.
முக்கிய அம்சங்கள்
Outlook revised to Positive from Stable by India Ratings and Research.Long-term rating affirmed at 'IND AA-' and short-term rating at 'IND A1+'.The credit rating applies to bank loan facilities amounting to ₹195.75 crore.Revision signals improving fundamental financial health and lower credit risk for the company.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive signal of the company's improving solvency and financial discipline. This upgrade could lead to lower borrowing costs for the company in the future.
Marksans Pharma achieved a significant milestone in FY26, crossing ₹3,000 crore in annual revenue with a 12.5% YoY growth. The company reported its highest-ever profitability, with Q4 EBITDA margins expanding to 22.8% driven by strong execution in North America and Australia. The balance sheet remains robust with ₹990 crore in cash and zero debt, supporting a final dividend recommendation of ₹0.90 per share. Management has reiterated a revenue target of ₹4,000 crore by FY28.
முக்கிய அம்சங்கள்
Annual revenue reached ₹2,951 crore (approx. ₹3,000 Cr), led by 24% growth in the North American market.Q4 FY26 EBITDA margin expanded by 491 bps YoY to 22.8%, reflecting strong operating leverage.Australia and New Zealand markets saw a massive 61.3% YoY growth in Q4 following entry into branded prescription generics.Maintains a debt-free status with cash and cash equivalents totaling ₹990 crore as of March 31, 2026.Management warned of 20-30% raw material cost inflation in petroleum-related ingredients for Q1 FY27 due to geopolitical issues.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful scale-up of the Teva facility and its entry into new regulated markets like Germany and Canada. While near-term raw material inflation is a headwind, the strong cash position and margin trajectory support a positive long-term outlook.
Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V. for €7.5 Million
Marksans Pharma has entered into a definitive agreement to acquire 100% of QliniQ B.V., a profitable Dutch pharmaceutical distributor, for a cash consideration of €7.5 million. QliniQ reported a revenue of €9.35 million and a net profit of €1.01 million for FY2025, showcasing a robust revenue CAGR of 41% since FY2023. This acquisition provides Marksans with direct front-end access to the Netherlands market, including established relationships with wholesalers, hospitals, and insurer-led tender channels. The deal is expected to close by June 15, 2026, and will be funded through cash reserves.
முக்கிய அம்சங்கள்
Acquisition of 100% share capital of QliniQ B.V. for a total consideration of €7.5 million.Target company reported FY2025 revenue of €9.35 million and net profit of €1.01 million with zero debt.QliniQ has achieved a high-growth trajectory with a revenue CAGR of approximately 41% between FY2023 and FY2025.Strategic expansion into the European Union through direct market access and EU GDP-compliant distribution infrastructure.Marksans reported consolidated total income of ₹3,033 crore and PAT of ₹420 crore for the financial year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic move that strengthens Marksans' forward-integration and European footprint at a reasonable valuation. Monitor the successful integration of QliniQ’s distribution network to see how it accelerates the commercialization of Marksans' existing product pipeline in the EU.
Marksans Pharma Hits Historic Triple: FY26 Revenue ₹3,033 Cr, PAT ₹420 Cr, Q4 PAT Up 64%
Marksans Pharma delivered record-breaking financial results for FY26, meeting its guidance with a total income of ₹3,033 crore and an all-time high PAT of ₹420 crore. The company showed exceptional momentum in Q4FY26, with PAT surging 64.3% YoY to ₹149 crore and EBITDA margins expanding significantly to 22.8%. Growth was fueled by 112 new SKU launches in the US and a strong recovery in the UK market. With a cash balance of ₹990 crore and the major capex cycle nearly complete, the company is well-positioned for sustainable future growth.
முக்கிய அம்சங்கள்
FY26 Total Income reached ₹3,033 crore, up 12.8% YoY, while Q4FY26 income rose 23.1% to ₹891 crore.Q4FY26 PAT jumped 64.3% YoY to ₹149 crore, with EBITDA margins improving by 491 bps to 22.8%.US & North America revenue grew to ₹1,533 crore in FY26, representing 52% of the total revenue mix.The company maintains a strong net cash position of ₹990 crore with ₹458 crore generated from operations in FY26.Successfully launched 112 new SKUs in the US and entered new markets including Germany, Canada, and Ireland.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the company's ability to deliver on its high-growth guidance. The strong cash position and completion of the capex cycle suggest potential for further market expansion or improved shareholder returns.
Marksans Pharma FY26 PAT Hits All-Time High of ₹420 Cr; Total Income Crosses ₹3,000 Cr Milestone
Marksans Pharma reported a milestone FY26 with total income reaching ₹3,033 crore, a 12.8% YoY increase, driven by strong growth in the US and Australia. The company achieved its highest-ever annual PAT of ₹420 crore and maintains a robust net cash position of ₹990 crore. Q4FY26 was particularly strong with a 64.3% YoY jump in PAT to ₹149 crore, supported by the launch of 11 new Rx brands in Australia and a recovery in the UK market. Management highlighted that the major capex cycle is nearly complete, positioning the company for sustainable long-term growth.
முக்கிய அம்சங்கள்
Total Income for FY26 reached ₹3,033 crore, crossing the ₹3,000 crore milestone for the first time.Q4FY26 PAT surged 64.3% YoY to ₹149 crore, with EBITDA margins expanding to 22.8%.US market remains the largest contributor (52% of revenue) with 112 new SKUs launched in FY26.Australia & NZ revenue grew 19.9% YoY, bolstered by the launch of the new Branded Prescription Division, Nova Pharma.Strong balance sheet with a cash balance of ₹990 crore and a net cash positive status.
👀 கவனிக்க வேண்டியவை
Investors should monitor the scaling of the new Rx division in Australia and the margin benefits from the completed capex cycle. The company's strong cash position and growth in the US OTC market provide a solid foundation for long-term value.
Marksans Pharma Recommends Final Dividend of Rs. 0.90 per Share for FY 2025-26
Marksans Pharma's Board has recommended a final dividend of Rs. 0.90 per equity share for the financial year ended March 31, 2026. This represents a 90% payout on the face value of Re. 1 per share. The company also confirmed the approval of its audited financial results for both the quarter and the full year with an unmodified audit opinion from MSKA & Associates LLP. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be processed within 30 days thereafter.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs. 0.90 per equity share, representing a 90% payout on face value.Audited financial results for Q4 and FY26 approved with an unmodified audit opinion.Dividend to be credited or dispatched within 30 days from the date of the Annual General Meeting.The Board meeting concluded on May 26, 2026, following the review of standalone and consolidated results.
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming AGM date and record date to ensure eligibility for the dividend payout. The 90% dividend recommendation reflects management's confidence in the company's cash flow and financial health.
Marksans Pharma has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP in 100 mg and 200 mg strengths. This product is a generic version of Pfizer's Tessalon Capsules and is used as a non-narcotic treatment for persistent cough and lung infections. The approval strengthens Marksans' upper respiratory portfolio in the US market, which is a key geography for the company. This development is expected to contribute to the company's export revenue growth and market share in the generic segment.
முக்கிய அம்சங்கள்
Final USFDA approval for Benzonatate Capsules USP in 100 mg and 200 mg dosages.Product is bioequivalent and therapeutically equivalent to Pfizer's Tessalon Capsules.Targets the upper respiratory segment for treating persistent cough and bronchitis.Expands the company's US portfolio which already includes CVS, CNS, and Pain Management.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive milestone for the company's US growth strategy. Monitor the management's guidance on the commercial launch timeline and potential market share capture.
Marksans Pharma Q3 FY26 Revenue Hits Record INR 754 Cr; EBITDA Margins Expand to 21.3%
Marksans Pharma reported a resilient Q3 FY26 with record operating revenue of INR 754.4 crores, a 10.6% YoY increase driven by strong US performance and seasonal demand. EBITDA margins expanded significantly by 217 bps to 21.3% due to operating leverage and softening raw material costs. The company remains debt-free with a robust cash balance of INR 824.2 crores and a strong US order book exceeding $220 million. Management is actively pursuing global expansion through new subsidiaries in Europe and Canada while targeting a long-term revenue milestone of INR 4,000 crores.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 10.6% YoY to an all-time high of INR 754.4 crores.EBITDA increased 23.2% YoY to INR 160.7 crores with margins expanding to 21.3%.US and North American markets grew 16.9% YoY, supported by a $220 million+ order book.The company remains debt-free with a cash surplus of INR 824.2 crores as of December 2025.Teva facility utilization is improving, currently contributing INR 560-600 crores toward an INR 800 crore target.
👀 கவனிக்க வேண்டியவை
Investors should view the margin expansion and strong US order book as positive indicators of operational efficiency. The company's debt-free status and significant cash reserves provide a strong cushion for its planned M&A and international expansion.
Marksans Pharma Q3 FY26: Revenue Up 10.6% YoY to ₹754.4 Cr, EBITDA Margin Hits 21.3%
Marksans Pharma reported a resilient Q3 FY26 with operating revenue growing 10.6% YoY to ₹754.4 crore, driven by strong volume growth in the US and Australia markets. EBITDA grew significantly by 23.2% YoY to ₹160.7 crore, with margins expanding by 217 bps to 21.3% due to favorable raw material costs and currency tailwinds. While quarterly PAT rose 8.2% YoY to ₹113.7 crore, the nine-month PAT remains down 7.1% YoY at ₹271.0 crore. The company maintains a robust cash balance of ₹824.2 crore and is expanding its global footprint with new subsidiaries in Europe and Canada.
முக்கிய அம்சங்கள்
Operating revenue increased 10.6% YoY to ₹754.4 cr, with US market revenue growing 16.9% to ₹412.4 cr.EBITDA rose 23.2% YoY to ₹160.7 cr, with EBITDA margins expanding 217 bps YoY to 21.3%.Quarterly PAT grew 8.2% YoY to ₹113.7 cr, though 9MFY26 PAT is down 7.1% YoY at ₹271.0 cr.Strong cash position of ₹824.2 cr as of December 31, 2025, with ₹263.2 cr cash generated from operations in 9MFY26.Australia and New Zealand business reported robust growth of 30.1% YoY, reaching ₹61.4 cr.
👀 கவனிக்க வேண்டியவை
Investors should monitor the sustainability of the 21% EBITDA margins and the progress of the new European and Canadian subsidiaries. The strong cash position and recovery in quarterly PAT suggest a positive trend despite a weaker 9-month performance.
Marksans Pharma Q3 PAT Surges 192% YoY to ₹609.11 Million; Revenue Up 38%
Marksans Pharma reported a stellar performance for Q3 FY26, with consolidated revenue from operations growing 38.3% YoY to ₹3,597.20 million. Net profit (PAT) witnessed a massive jump of 192% YoY, reaching ₹609.11 million compared to ₹208.41 million in the same period last year. The company is actively pursuing global expansion, having incorporated new subsidiaries in Ireland and Canada in January 2026. Despite a one-time impact of ₹28.10 million from new labour code provisions, the company's operational efficiency remains high with an EPS of ₹1.34.
முக்கிய அம்சங்கள்
Revenue from operations grew 38.3% YoY to ₹3,597.20 million in Q3 FY26.Net Profit (PAT) increased significantly to ₹609.11 million from ₹208.41 million in the year-ago period.Earnings Per Share (EPS) rose to ₹1.34 for the quarter, up from ₹0.46 in Q3 FY25.Incorporated two new wholly-owned subsidiaries in Ireland and Canada in January 2026 to drive international expansion.Accounted for a ₹28.10 million incremental impact due to the implementation of New Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong triple-digit profit growth and aggressive international expansion. The stock remains a positive prospect for long-term investors given the consistent improvement in margins and global footprint.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
